Repligen (RGEN) Tops Q1 EPS by 5c, Lowers FY23 Guidance

Repligen (NASDAQ: RGEN) reported Q1 EPS of $0.64, $0.05 better than the analyst estimate of $0.59. Revenue for the quarter came in at $182.7 million versus the consensus estimate of $182.19 million.

GUIDANCE:

Repligen sees FY2023 EPS of $2.35-$2.42, versus the consensus of $2.64. Repligen sees FY2023 revenue of $720-760 million, versus the consensus of $780 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• zSpace, Inc. (ZSPC) Reports Q2 results